StockNews.com initiated coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a research report sent to investors on Sunday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
MediciNova Price Performance
Shares of MNOV stock opened at $1.36 on Friday. The firm’s 50-day moving average is $1.40 and its two-hundred day moving average is $1.58. MediciNova has a 12 month low of $1.26 and a 12 month high of $2.66. The company has a market capitalization of $66.46 million, a PE ratio of -7.97 and a beta of 0.75.
MediciNova (NASDAQ:MNOV – Get Free Report) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. Sell-side analysts forecast that MediciNova will post -0.23 EPS for the current year.
Hedge Funds Weigh In On MediciNova
About MediciNova
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Featured Stories
- Five stocks we like better than MediciNova
- Most Volatile Stocks, What Investors Need to Know
- High-Yield Texas Instruments Could Hit New Highs Soon
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Consumer Discretionary Stocks Explained
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.